HLS THERAPEUTICS INC (HLS.CA) Fundamental Analysis & Valuation

TSX:HLS • CA40390B1094

Current stock price

4.4 CAD
0 (0%)
Last:

This HLS.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. HLS.CA Profitability Analysis

1.1 Basic Checks

  • HLS had negative earnings in the past year.
  • In the past year HLS had a positive cash flow from operations.
  • In the past 5 years HLS always reported negative net income.
  • Each year in the past 5 years HLS had a positive operating cash flow.
HLS.CA Yearly Net Income VS EBIT VS OCF VS FCFHLS.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M

1.2 Ratios

  • HLS has a Return On Assets of -10.07%. This is comparable to the rest of the industry: HLS outperforms 48.48% of its industry peers.
  • HLS has a Return On Equity (-22.87%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -10.07%
ROE -22.87%
ROIC N/A
ROA(3y)-11.74%
ROA(5y)-9%
ROE(3y)-24.86%
ROE(5y)-18.35%
ROIC(3y)N/A
ROIC(5y)N/A
HLS.CA Yearly ROA, ROE, ROICHLS.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10 -20

1.3 Margins

  • The Gross Margin of HLS (81.87%) is better than 100.00% of its industry peers.
  • In the last couple of years the Gross Margin of HLS has declined.
  • HLS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 81.87%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.41%
GM growth 5Y-2.67%
HLS.CA Yearly Profit, Operating, Gross MarginsHLS.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. HLS.CA Health Analysis

2.1 Basic Checks

  • HLS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, HLS has less shares outstanding
  • HLS has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for HLS has been reduced compared to a year ago.
HLS.CA Yearly Shares OutstandingHLS.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
HLS.CA Yearly Total Debt VS Total AssetsHLS.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • Based on the Altman-Z score of -0.96, we must say that HLS is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -0.96, HLS perfoms like the industry average, outperforming 48.48% of the companies in the same industry.
  • HLS has a debt to FCF ratio of 4.28. This is a neutral value as HLS would need 4.28 years to pay back of all of its debts.
  • HLS has a Debt to FCF ratio of 4.28. This is amongst the best in the industry. HLS outperforms 81.82% of its industry peers.
  • A Debt/Equity ratio of 0.80 indicates that HLS is somewhat dependend on debt financing.
  • The Debt to Equity ratio of HLS (0.80) is worse than 66.67% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.8
Debt/FCF 4.28
Altman-Z -0.96
ROIC/WACCN/A
WACC8.1%
HLS.CA Yearly LT Debt VS Equity VS FCFHLS.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

  • A Current Ratio of 1.17 indicates that HLS should not have too much problems paying its short term obligations.
  • With a Current ratio value of 1.17, HLS is not doing good in the industry: 75.76% of the companies in the same industry are doing better.
  • A Quick Ratio of 0.87 indicates that HLS may have some problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 0.87, HLS is doing worse than 60.61% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.17
Quick Ratio 0.87
HLS.CA Yearly Current Assets VS Current LiabilitesHLS.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. HLS.CA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 34.78% over the past year.
  • The Revenue has decreased by -1.92% in the past year.
  • HLS shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 0.88% yearly.
EPS 1Y (TTM)34.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
Revenue 1Y (TTM)-1.92%
Revenue growth 3Y-1.91%
Revenue growth 5Y0.88%
Sales Q2Q%-4.08%

3.2 Future

  • The Earnings Per Share is expected to grow by 20.32% on average over the next years. This is a very strong growth
  • HLS is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.53% yearly.
EPS Next Y36.47%
EPS Next 2Y26.53%
EPS Next 3Y24.26%
EPS Next 5Y20.32%
Revenue Next Year-3.3%
Revenue Next 2Y3.34%
Revenue Next 3Y6.49%
Revenue Next 5Y4.53%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
HLS.CA Yearly Revenue VS EstimatesHLS.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 20M 40M 60M
HLS.CA Yearly EPS VS EstimatesHLS.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 -0.5

More info and screens

Find the best growth stocksShow best growing peers

3

4. HLS.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • HLS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year HLS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HLS.CA Price Earnings VS Forward Price EarningsHLS.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

  • HLS's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. HLS is cheaper than 69.70% of the companies in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of HLS indicates a rather cheap valuation: HLS is cheaper than 87.88% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 7.95
EV/EBITDA 9.03
HLS.CA Per share dataHLS.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as HLS's earnings are expected to grow with 24.26% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.53%
EPS Next 3Y24.26%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. HLS.CA Dividend Analysis

5.1 Amount

  • HLS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

HLS.CA Fundamentals: All Metrics, Ratios and Statistics

HLS THERAPEUTICS INC

TSX:HLS (3/16/2026, 7:00:00 PM)

4.4

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-12
Earnings (Next)05-06
Inst Owners43.33%
Inst Owner ChangeN/A
Ins Owners0.53%
Ins Owner ChangeN/A
Market Cap137.59M
Revenue(TTM)55.85M
Net Income(TTM)-14.12M
Analysts80
Price Target8.35 (89.77%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-48.51%
Min EPS beat(2)-69.73%
Max EPS beat(2)-27.3%
EPS beat(4)0
Avg EPS beat(4)-31.47%
Min EPS beat(4)-69.73%
Max EPS beat(4)-11.88%
EPS beat(8)1
Avg EPS beat(8)-25.77%
EPS beat(12)1
Avg EPS beat(12)-56.65%
EPS beat(16)1
Avg EPS beat(16)-50.22%
Revenue beat(2)0
Avg Revenue beat(2)-4.93%
Min Revenue beat(2)-6.61%
Max Revenue beat(2)-3.24%
Revenue beat(4)0
Avg Revenue beat(4)-3%
Min Revenue beat(4)-6.61%
Max Revenue beat(4)-0.17%
Revenue beat(8)1
Avg Revenue beat(8)-4.67%
Revenue beat(12)2
Avg Revenue beat(12)-4.36%
Revenue beat(16)2
Avg Revenue beat(16)-5.03%
PT rev (1m)0%
PT rev (3m)9.9%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.74%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-0.01%
Revenue NY rev (3m)-0.01%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.8
P/FCF 7.95
P/OCF 7.27
P/B 1.63
P/tB N/A
EV/EBITDA 9.03
EPS(TTM)-0.62
EYN/A
EPS(NY)-0.34
Fwd EYN/A
FCF(TTM)0.55
FCFY12.57%
OCF(TTM)0.6
OCFY13.75%
SpS2.44
BVpS2.7
TBVpS-2.1
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -10.07%
ROE -22.87%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 81.87%
FCFM 22.64%
ROA(3y)-11.74%
ROA(5y)-9%
ROE(3y)-24.86%
ROE(5y)-18.35%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.41%
GM growth 5Y-2.67%
F-Score6
Asset Turnover0.4
Health
Industry RankSector Rank
Debt/Equity 0.8
Debt/FCF 4.28
Debt/EBITDA 3.1
Cap/Depr 5.44%
Cap/Sales 2.12%
Interest Coverage N/A
Cash Conversion 86.75%
Profit Quality N/A
Current Ratio 1.17
Quick Ratio 0.87
Altman-Z -0.96
F-Score6
WACC8.1%
ROIC/WACCN/A
Cap/Depr(3y)0.36%
Cap/Depr(5y)20.34%
Cap/Sales(3y)0.19%
Cap/Sales(5y)11.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
EPS Next Y36.47%
EPS Next 2Y26.53%
EPS Next 3Y24.26%
EPS Next 5Y20.32%
Revenue 1Y (TTM)-1.92%
Revenue growth 3Y-1.91%
Revenue growth 5Y0.88%
Sales Q2Q%-4.08%
Revenue Next Year-3.3%
Revenue Next 2Y3.34%
Revenue Next 3Y6.49%
Revenue Next 5Y4.53%
EBIT growth 1Y47.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year287.18%
EBIT Next 3Y64.45%
EBIT Next 5Y42.36%
FCF growth 1Y-17.8%
FCF growth 3Y-20.24%
FCF growth 5Y-19.65%
OCF growth 1Y-11.25%
OCF growth 3Y-21.32%
OCF growth 5Y-21.24%

HLS THERAPEUTICS INC / HLS.CA Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for HLS THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to HLS.CA.


What is the valuation status for HLS stock?

ChartMill assigns a valuation rating of 3 / 10 to HLS THERAPEUTICS INC (HLS.CA). This can be considered as Overvalued.


What is the profitability of HLS stock?

HLS THERAPEUTICS INC (HLS.CA) has a profitability rating of 2 / 10.


How sustainable is the dividend of HLS THERAPEUTICS INC (HLS.CA) stock?

The dividend rating of HLS THERAPEUTICS INC (HLS.CA) is 0 / 10 and the dividend payout ratio is 0%.